Cancer-Killing virus trial launches for patients out of options
NCT ID NCT06444815
First seen Apr 26, 2026 · Last updated Jun 20, 2026 · Updated 12 times
Summary
This early-phase trial is testing a new treatment called VET3-TGI, a virus engineered to attack cancer cells. It is given alone or with the immunotherapy drug atezolizumab to up to 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Community Health Network
RECRUITINGIndianapolis, Indiana, 46250, United States
Contact
Contact Phone: •••-•••-••••
-
Mary Crowley Cancer Research
RECRUITINGDallas, Texas, 75230, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UC Irvine Health
RECRUITINGOrange, California, 92868, United States
Contact
Contact Email: •••••@•••••
-
UPMC- Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Email: •••••@•••••
Contact
-
USC/Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Email: •••••@•••••
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Email: •••••@•••••
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VET3-TGI (a modified virus that targets and kills cancer cells) and atezolizumab (an immunotherapy drug)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early, first-in-human phase 1 trial with only 60 participants. The virus has never been tested in people before, so safety and effectiveness are unknown. It may not work or could cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.